Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Preferred Stock

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on March 26, 2025.

Summary

• Provectus Biopharmaceuticals CEO Edward Pershing filed a Form 4 detailing changes in beneficial ownership.
• On March 26, 2025, Pershing converted an 8% unsecured convertible promissory note into 150,975 shares of Series D-1 Convertible Preferred Stock.
• The conversion price was $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless earlier converted.
• Following the transaction, Pershing directly owns 2,055,987 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The conversion of debt to equity could be seen as a positive sign, but without more context, it's difficult to assess the overall impact.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a conversion of debt to equity by the CEO, which can be interpreted in various ways depending on the company's financial situation and future plans.

Stakeholder Impact

• The conversion of the promissory note into preferred stock could dilute existing shareholders if the preferred stock is later converted into common stock.

Key Dates

Keywords

Form 4, beneficial ownership, Edward Pershing, CEO, Provectus Biopharmaceuticals, PVCT, Series D-1 Convertible Preferred Stock, promissory note, conversion